Rachman Ilya M
Known title: CEO and ChairmanCIK: 0001889334
Rachman Ilya M's purchase track record
How the stock did after each of Rachman Ilya M's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 7 since December 20, 2021
Stock higher 6 months later
71%
3 months: 57%
Median 6-month return
+23.8%
3 months: +12.7%
Beat the S&P 500
71%
median +16.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/10/2025 | IMMX | $5K | +55.4% | +21.6% | +5.5% |
| 9/17/2025 | IMMX | $5K | +183.7% | +382.6% | +0.4% |
| 6/18/2025 | IMMX | $5K | -18.0% | +132.6% | +12.4% |
| 6/4/2024 | IMMX | $12K | +12.7% | +23.8% | +14.3% |
| 5/14/2024 | IMMX | $10K | -15.4% | -21.8% | +14.1% |
| 11/14/2022 | IMMX | $5K | +131.1% | +100.0% | +4.5% |
| 12/20/2021 | IMMX | $13K | -31.7% | -29.8% | -17.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMMX | ▲ Buy | Open Market | 746 | $5K | 12/10/2025 | View on chart |
| IMMX | ▲ Buy | Open Market | 2,500 | $5K | 9/17/2025 | View on chart |
| IMMX | ▲ Buy | Open Market | 2,178 | $5K | 6/18/2025 | View on chart |
| IMMX | ▲ Buy | Open Market | 2,600 | $6K | 6/7/2024 | View on chart |
| IMMX | ▲ Buy | Open Market | 3,300 | $6K | 6/4/2024 | View on chart |
| IMMX | ▲ Buy | Grant | 218,359 | — | 5/20/2024 | View on chart |
| IMMX | ▲ Buy | Open Market | 4,300 | $10K | 5/14/2024 | View on chart |
| IMMX | ▲ Buy | Open Market | 4,050 | $4K | 11/14/2022 | View on chart |
| IMMX | ▲ Buy | Open Market | 1,000 | $950 | 11/14/2022 | View on chart |
| IMMX | ▲ Buy | Open Market | 150 | $149 | 11/14/2022 | View on chart |
| IMMX | ▲ Buy | Open Market | 2,500 | $13K | 12/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
IMMX Holds Shareholder and Analyst Call
Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.
IMMX Holds Shareholder and Analyst Call. Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.